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Abstract
BACKGROUND: Measurements of GFR may be performed with a slope/intercept method (S/I), using only two blood samples 
taken in strictly defined time points. The aim of the study was to modify this method in order to extend time intervals suitable for 
blood sampling. Modification was based on a variation of a Russel et al. model parameter, selection of time intervals suitable 
for blood sampling and assessment of uncertainty of calculated results. 
MATERIAL AND METHODS: Archived values of GFR measurements of 169 patients with different renal function, from 5.5 to 
179 mL/min, calculated with a multiple blood sample method were used. Concentrations of a radiopharmaceutical in consecutive 
minutes, from 60th to 190th after injection, were calculated theoretically, using archived parameters of biexponential functions 
describing a decrease in 99mTc-DTPA concentration in blood plasma with time. These values, together with injected activities, 
were treated as measurements and used for S/I clearance calculations. Next, values of S/I clearance were compared with the 
multiple blood sample method in order to calculate suitable values of exponent present in a Russel’s model, for every combina-
tion of two blood sampling time points. A model was considered accurately fitted to measured values when SEE ≤ 3.6 mL/min. 
Assessments of uncertainty of obtained results were based on law of error superposition, taking into account mean square 
prediction error and also errors introduced by pipetting, time measurement and stochastic radioactive decay. 
RESULTS: The accepted criteria resulted in extension of time intervals suitable for blood sampling to: between 60 and 90 min-
utes after injection for the first sample and between 150 and 180 minutes for the second sample. Uncertainty of results was 
assessed as between 4 mL/min for GFR = 5–10 mL/min and 8 mL/min for GFR = 180 mL/min. 
CONCLUSIONS: Time intervals accepted for blood sampling fully satisfy nuclear medicine staff and ensure proper deter-
mination of GFR. Uncertainty of results is entirely acceptable and for high GFR values even comparable with uncertainty of 
multi-sample measurements.
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Background
Renal clearance is a measure of renal efficiency in elimination 
of metabolites from blood. For this reason measurement of renal 
clearance is necessary in a clinical practice. Clearance of blood 
plasma from metabolites takes place in two parts of a nephron, 
as a result of two different processes; therefore, it is possible to 
determine clearance values specific for those processes: glo-
merular filtration rate (GFR), tubular extraction rate (TER) and also 
effective renal plasma flow (ERPF) combining both mentioned 
above renal functions. 
Glomerular filtration rate is considered the best measure of renal 
function among types of clearance specified above, in both healthy 
and sick people. However, measurement of GFR in clinical practice 
is troublesome. For this reason renal function is usually assessed 
from serum creatinine level. In order to make this troublesome 
measurement of GFR easier, several equations were developed, 
allowing the assessment of GFR from serum creatinine level, patient 
age, sex and body size [1–7]. Although in general those equa-
tions can be used to assess renal function in clinical practice, one 
should keep in mind that they were developed after assumption 
of several simplifications and therefore calculated values may be 
burdened with a relatively large error. Moreover, serum creatinine 
level depends not only on filtration rate, but also some other factors 
43www.journals.viamedica.pl/nuclear_medicine_review
Marian J Surma et al., Modification of GFR measurement
Original
like protein consumption [8]. For these reasons, precision and 
accuracy of GFR assessed from serum creatinine level are poor. 
Substances labeled with radionuclides proved to be highly use-
ful in measurements of clearances. They allowed the assessment 
of renal clearance after a single injection of a radiopharmaceutical, 
without measurements of activity secreted with urine [9–20].
First methods applied for renal clearance assessments were 
based on a two-compartment open model of distribution and 
elimination of endogenous creatinine, developed by Sapirstein et 
al. [9], which was further adapted for radiopharmaceutical applica-
tions [10–14]. Those methods are considered “gold standard” and 
are still in use. They apply a formula which takes into account activity 
of administered radiopharmaceutical and also its concentration in 
blood plasma measured in several [9–12] blood samples taken from 
5 minutes to 180 minutes (sometimes even longer) after injection. 
Those methods are referred to as multi-sample techniques.
In studies aiming at facilitation of measurement of GFR several 
authors reduced numbers of blood samples. They mostly ap-
plied a method named slope/intercept (S/I), which requires two 
or three blood samples [12–14]. This simplification is with no 
doubt beneficial, but, on the other hand, authors of those proce-
dures recommend taking blood samples in strictly determined 
time points after injection. In everyday practice of nuclear medicine 
departments such requirements not always can be met. Also a long 
stay in a healthcare facility, sometimes even exceeding 5 hours, can 
be cumbersome for a patient. Those facts encouraged us to work 
on a modification of a two-sample method introduced by Russel et 
al. [15] in order to extend time intervals suitable for blood sampling 
with possible shortening of patient’s stay in a nuclear medicine 
department. Moreover, introduction of targeted radionuclide therapy 
into clinical practice, where kidneys are often critical organs and 
need monitoring [16, 17] increases requirement for relatively sim-
ple, quick and reliable method for measurement of renal function. 
The aim of the work was to modify a two-sample method used 
for measurement of GFR, introduced by Russel et al. [15]. This ob-
jective was achieved by the following partial goals:
1. Finding a formula variating a parameter of an equation pre-
senting relationship between a reference clearance value and 
a value calculated from an S/I method. 
2. Determination of time intervals suitable for blood sampling 
providing S/I based clearance calculations close to reference 
values.
3. Assessment of uncertainty of GFR values calculated with 
a modified method. 
Material and methods
Theoretical basis
GFR calculations are based on a formula derived from 
a two-compartmental open model of a distribution and excretion 
of a substance: 
GFR =  A  (1)
 
 A1 +  A2
 b1  b2
where: A denotes activity of administered radiopharmaceuti-
cal; A1, b1, A2, b2 are parameters of a function describing a decline 
of radiopharmaceutical concentration in blood plasma with time. 
C(t) = A1e
–b1t + A2e
–b2t  (2)
A first component of the function (2), A1e
–b1t, is referred to 
as a quick phase, because its values decrease rapidly to zero and 
therefore can be neglected in later parts of a study, typically 60 min 
after injection. A decrease in a second component, A2e
–b2t, is much 
slower; this is why it is referred to as a slow phase. Calculations of 
function parameters for a given patient are based on measure-
ments of blood plasma samples taken several times after injection, 
at early and late stage of a study, fitting of a mathematical formula of 
a function (2) to measurements; parameters calculated in this way, 
together with administered activity, can be used in formula (1) for 
calculation of GFR. 
A quick phase vanishes rapidly so a contribution of a low phase 
to a denominator of formula (1) is by far higher than of the quick 
one. This is why some authors recommend calculation of renal 
clearence based on a slow phase only [12–15, 18]. They use the 
following formula for this purpose: 
C =  A  (3)
 
 A2
 b2
In order to calculate parameters A2 and b2 only two blood sam-
ples are necessary, taken in a late phase of a study when contribu-
tion of a quick phase is negligible. Cl symbol applies to a clearance 
value determined with an S/I method from two blood samples. 
From a comparison of equations (1) and (3) it is clear that Cl val-
ue is larger than GFR, so Cl should be corrected in order to be closer 
to GFR. Such corrections were proposed by Brøchner-Mortenson 
[17] and Hagstam et al. [18] who applied a quadratic correction 
according to an equation:
GFR = g • Cl + f • Cl2 (4)
Correction coefficients f and g were determined empirically. So 
for a first blood sample taken 90 or 120 minutes, and the second 
one taken 240 minutes after injection, Brøchner-Mortenson [17], 
Hangston et al. [18] and Tepe et al. [19] calculated the following 
values for g and f coefficients, respectively: 0.990778 and –0.001218 
when GFR was measured in adults and 1.01 and –0.0017 when it 
concerned children. 
However, Russell et al. [15] proposed exponential correction 
according to an equation:
GFR = Cla (5)
with value of correction parameter 0 < a < 1, which is also 
determined empirically. For blood samples taken in T1 ≈60 min and 
T2 ≈180 min the authors obtained a =0.979.
Values of exponent a as well as f and g coefficients may be dif-
ferent for other times of blood sampling because, although a quick 
phase of a curve is declining fast, it differs between particular time 
points and its values can affect correction parameters. So, in order 
to allow for blood sampling in time intervals instead of time points, 
correction parameters should vary with time.
We applied in our work modification proposed by Russell et 
al. [15].
The study was approved by the Medical University Bioeth-
ics Committee.
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Uncertainties DGFRT1\2, DGFRp and DGFRs were assessed from 
differential of formula (6) taking into account also formula (3), as-
suming that time measurements errors did not exceed 10 s, pipet-
ting error was equal to 2%, and uncertainty of radioactive sample 
measurement was not greater than 1%. Own experience of the 
authors of this work points out that uncertainties of those measure-
ments are smaller in practice. However, it is better to overestimate 
potential errors than to neglect them. 
Results
Figure1 presents an illustrative relationship between Cl60, 125 
(obtained for times of blood sampling T1 = 60 min and 
T2 = 125 min) and GFR values together with a fitted curve. A cri-
terion SEE ≤ 3.6 mL/min resulted in selection of the following time 
intervals: for T1 between 60 min and 90 min and for T2 between 
150 min and 190 min. Figure 2 illustrates how SEE changes with 
Archived data
Archived data of 169 patients who underwent multi-sample 
studies of GFR measured with 99mTc-DTPA obtained from kits pro-
duced by POLATOM were used. Studies were performed in the 
Department of Nuclear Medicine of Central Teaching Hospital of 
Medical University in Łódź. GFR values were included between 
5.5 mL/min and 179 mL/min. 
An archive of every patient contained GFR values determined 
with a multi-sample method, coefficients A1, b1, A2 and b2 of the func-
tion (2) describing how a concentration of a radiopharmaceutical 
in blood plasma was changing with time, as well as count rate [in 
cpm] obtained from activity A administered to a patient. Using those 
data, concentrations of a radiopharmaceutical were calculated [in 
cpm/mL] for every fifth minute between 30 and 190 minutes, which 
were then treated as measured values.
Paired concentrations Ck, Cl in time points Tk,Tl for k = 30, 35, 
40,...., 120 and l = 100, 105, 110, 115,..., 190, with l ≥ k+15 (e.g. 
C30 and C100 are concentrations measured from a first blood sample 
taken in time point T30 = 30 min and a second blood sample taken 
in T100 = 100 min) with time difference Tl–Tk not smaller than 15 min, 
as well as administered activity were used for calculations of Clk, l. 
When A2 and b2 are calculated from Ck and Cl in samples taken in 
time points Tk and Tl, respectively, equation (3) after transformation 
will have the following form:

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When Clk, l values were already calculated for respective GFR 
values (511 Clk, l values for every GFR), exponential formula (5) 
was used to determine a functional relationship between these val-
ues. Fitting of equations was based on determination of exponent α 
in such a way that a sum of squares was minimal. Sum of squares of 
remainders allows determining a standard error of estimate (SEE) 
of fitting to measured values. These calculations were made using 
Statistica software.
Selection of time intervals
Time intervals for which a standard error of the estimate (SEE) 
was not larger than 3.6 mL/min were selected. This criterion is in agree-
ment with a recommendation published by Brøchner-Mortenson [17]. 
A set of SEE values for which the above criterion is met 
was used to create a formula presenting relationship between SEE 
and selected values of T1 and T2 (time points of first and second 
blood sampling, respectively) — SEE (T1, T2). This function had 
a form of a polynomial of a degree for which a coefficient of deter-
mination was not lower than 0.996.
Assessment of uncertainty of modified GFR 
measurement
Uncertainty DGFR of modified GFR measurements was estimat-
ed using law of error superposition, taking into account prediction 
error Spr, determined by SEE (see Appendix) and errors made during 
study performance resulting from uncertainties of blood sampling 
times DGFRT1 and DGFRT2, pipetting DGFRp and a stochasticity of 
radioactive decay DGFRs, so:
22222
)()()()()(
21 sTTppr
GFRGFRGFRGFRSGFR 
Figure 1. GFR and Cl values obtained for blood samples taken 
in two time points: T1 = 60 min and T2 = 125 min together with 
a curve presenting a relation between those variables. R2 = 0.98074, 
SEE = 3.37 mL/min
Figure 2. Relation between SEE and time points of first (T1) and 
second (T2) blood sampling
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time of blood sampling and in Table 1 its values for ends of time 
intervals are presented. For other pairs of blood sampling times, 
values of SEE will be intermediate. 
A relation between SEE and blood sampling times T1 and T2 
is characterized by an experimentally derived polynomial function 
(see: Selection of time intervals):
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In Table 2 values of exponent a calculated for ends of time inter-
vals are presented. It can be seen that a difference between maxi-
mal and minimal values of this exponent does not exceed 0.0017. 
This is why a constant value of exponent a equal to its mean value 
of 0.9812 was accepted instead of varying it with sampling times. 
SEE values given in Table 1 and calculated from formula (7) 
make up the smallest width of so called error corridor (referred 
to as prediction error) achieved for mean abscissa and ordinate 
values. For minimal and maximal values of GFR a width of an error 
corridor (prediction error) increases only by 0.1%, which equals to 
0.0003 mL/min. For this reason a constant prediction error for 
a whole range of calculated clearence values equal to SEE was ac-
cepted while assessing the uncertainty of modified calculations of 
GFR results. 
Figure 3 illustrates how uncertainty of GFR measurement 
changes with its value, when blood sampling is made in 90 minute 
and 150 minute after injection. It can be seen that a whole uncer-
tainty is determined mostly by the prediction error and pipetting 
error and to a much lesser extent by timing errors. 
Figure 4 presents how a whole relative uncertainty (precision) of 
GFR measurement changes, when blood sampling is made at least 
(90 and 150 minutes) and most (60 and 180) appropriate times after 
injection. Differences between those values are considerable for low 
GFR values — from 5 mL/min to 15 mL/min and are equal to 11% 
and 6%, respectively. Then, above 15 mL/min these differences in 
precision decline to 2.5% for GFR ≈20 mL/min, to 2% for GFR 
≈30 mL/min, to 1.5% for GFR ≈45 mL/min and to 0.25% for GFR 
≈180 mL/min. It corresponds to differences in absolute uncertain-
ties at least and most appropriate measurement conditions from 
about 1 mL/min to 0.5 mL/min. For other T1, T2 pairs taken from 
earlier selected time intervals the whole uncertainties are compa-
rable and do not exceed mentioned above values. 
Discussion
Brøchner-Mortensen as well as other authors proved that 
it is possible to measure GFR after taking only two blood sam-
ples 3–5 hours after injection of 51Cr-EDTA or 99mTc-DTPA [15, 
18–20]. Analyses presented in this work confirm this possibility, 
also when blood samples are taken in other time points than those 
recommended by the authors mentioned above, preserving equal 
value of a standard error of estimate (SEE), namely 3.6 mL/min, 
Figure 3. Relation between total uncertainty of measurement (solid 
line) and its components: prediction error (dashed line), pipetting 
uncertainty (dotted line), time uncertainty (double dotted line) and 
measured GFR values when blood samples are taken 90 and 150 
minutes after injection
Figure 4. Relative total uncertainty of GFR measurement in relation 
to its values for blood samples taken 90 and 150 minutes after 
injection (a), 60 and 180 minutes after injection (b). Line (c) presents 
a difference between (a) and (b)
Table 1. SEE values [mL/min] determined for ends of time intervals
T2 T1
60 min 90 min
150 min 3.08 3.5
180 min 2.91 3.47
Table 2. Values of a exponents determined for ends of time intervals
T2 T1
60 min 90 min
150 min 0.98162 0.98052
180 min 0.98228 0.98068
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as recommended by Brøchner-Mortensen et al. [17]. This criterion 
is met when a first blood sample is taken in time 60 min ≤ T1 ≤ 90 min, 
and the second one at 150 min ≤ T2 ≤ 180 minutes after injection.
Calculated values of exponent a vary from 0.98052 for a shortest 
time interval between blood samplings (T1 = 90 min, T2 = 150 min) 
to 0.98228 for blood samples taken 60 and 180 minutes after injec-
tion. Those values, although slightly higher, are in good agreement 
with a value 0.979 presented in a publication by Russel et al. [15].
Minor, smaller than 0.2%, variability of exponent a in determined 
time intervals allows using its mean value, namely 0.9812, for time 
pairs T1, T2 instead of calculating its exact value. Chantler et al. [11] 
proceed in the same way, even when blood samples are taken in 
times points different from those recommended by Russell et al. [15]. 
However, a mean value used instead of a calculated one for 
a given time pair T1 and T2 changes accuracy of a resultant value, 
especially when blood samples are taken at ends of time intervals. 
Our analysis proved that accuracy of calculated values in case of 
most unfavorable times T1 and T2 will not exceed 1 mL/min when 
GFR ≈180 mL/min. This inaccuracy decreases with decline of GFR 
values and reaches 0.02 mL/min for GFR ≈10 mL/min. Such a small 
change of accuracy does not affect interpretation of calculated GFR 
values. On this basis the modified method for GFR calculation may 
be considered sufficiently accurate. 
In every method used for measurement of a given quantity 
an uncertainty of its results should be also assessed. This task 
was also performed in this work. As mentioned earlier, a model of 
a relation between modified and full measurement of GFR, referred 
to as a prediction error determined by SEE, as well as manual 
activities contribute to uncertainty of results. 
Obtained results point out that a prediction error determined by 
SEE for optimal time points of blood sampling is equal 2.9 mL/min 
and for less favorable times it reaches 3.5 mL/min for middle 
values of GFR. Moreover, for extremely low and high GFR values, 
10 mL/min and 180 mL/min, respectively, a prediction error in-
creases only by 0.001 mL/min, for optimal as well less favorable 
times of blood sampling. For this reason a prediction error can be 
considered constant for the whole range of analyzed GFR values, 
its value depending only on blood sampling times. This error cannot 
be completely eliminated, only minimized. This is why possibly long 
time laps between blood samplings are recommended. 
Manual activities are another source of a significant error. 
Analysis of uncertainties revealed a relatively high contribution of 
pipetting in this error. This contribution grows with GFR value and for 
high clearance values it surpasses a prediction error. Relations pre-
sented in Figure 4 were calculated for 2% pipetting precision, which 
is a realistic value of this kind of error. 
As can be seen in Figure 3, errors in time measurements affect 
overall uncertainty of measurements to a lesser extent. Accepted 
uncertainty of time measurement was 10 seconds, an excessive 
value for vast majority of cases. 
After considering all partial uncertainties and adding them 
according to a law of error superposition a relation between total 
absolute uncertainty of GFR measurement and its value was ob-
tained (Fig. 3). As can be seen, uncertainty of absolute measure-
ment increases with its value, from about 4 mL/min for GFR equal 
to 5–10 mL/min to about 8 mL/min for GFR = 180 mL/min, when 
blood samples are taken 90 and 150 minutes after injection. 
When blood sampling is made at more favorable time points, like 
60 minutes and 180 minutes after injection, a curve presenting 
uncertainty of measurement is located about 0.5 mL/min lower. 
So, for time intervals selected earlier uncertainties of measurement 
are almost equal. 
Precision is a metrological characteristic of a measurement 
procedure. In this case a relative measurement uncertainty may be 
accepted as a measurement precision. Figure 4 presents its relation 
to GFR values for optimal and most unfavorable time points of blood 
sampling. When samples are taken at optimal time points (60 and 
180 minutes), a relative uncertainty of measurement falls abruptly 
from 55% for GFR = 5 mL/min to 10% for GFR = 30 mL/min and 
then mildly to about 5% for GFR = 180 mL/min (Fig. 4, solid line). 
When blood samples are taken at least favorable time points (90 
and 150 minutes) a shape of a curve is similar but its values are 
higher by about 10%. For higher GFR values differences be-
tween uncertainties decrease and for GFR = 180 mL/min both 
curves overlap. All in all, a precision of GFR measurement with 
a modified method is satisfactory for blood sampling at all time 
points within earlier determined time intervals. Moreover, for 
GFR > 40 mL/min a measurement precision is comparable with 
precision of a multi-sample method [21].
It should be also mentioned that results of GFR measurement, 
in order to be comparable among patients, should be normalized 
to patient body surface, which can be calculated from the Haycock 
[22] formula: 
BS = 0.024265 • H0.3964M0.5378
where BS — body surface in m2, H — patient height in cm, 
M — body mass in kg.
Conclusions
1. Time intervals selected for blood sampling, 60 to 90 minutes for 
the first and 150 to 180 for the second one, fully satisfy nuclear 
medicine staff. Three-hour study duration is acceptable for 
patients. 
2. Uncertainties of measurements when blood samples are taken 
in specified above time intervals are low, and for high GFR 
values even comparable with uncertainties of multi-sample 
method. 
3. The proposed modification of GFR measurement method 
provides credible results. 
4. A software applying formulae used in this method can be coded 
easily and applied in practice.
Appendix
In statistics a mean squared prediction error Spr of a smoothing 
or curve fitting procedure is the expected value of the squared dif-
ference between the fitted values and the values of the smoothed 
function.
References
1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 
creatinine. Nephron. 1976; 16(1): 31–41, indexed in Pubmed: 1244564.
2. Parker RA, Bennett WM, Porter GA. Clinical estimation of creatinine clear-
ance without urine collection. Dialysis and Transplantation. 1980; 9: 251–2.
47www.journals.viamedica.pl/nuclear_medicine_review
Marian J Surma et al., Modification of GFR measurement
Original
3. Gault MH, Longerich LL, Harnett JD, et al. Predicting glomerular function 
from adjusted serum creatinine. Nephron. 1992; 62(3): 249–256, indexed 
in Pubmed: 1436333.
4. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate 
glomerular filtration rate from serum creatinine: a new prediction equation. 
Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 
130(6): 461–470, indexed in Pubmed: 10075613.
5. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Dis-
ease Epidemiology Collaboration). A new equation to estimate glomerular 
filtration rate. Ann Intern Med. 2009; 150(9): 604–612, indexed in Pubmed: 
19414839.
6. Levey AS. Measurement of renal function in chronic renal disease. Kidney 
Int. 1990; 38(1): 167–184, indexed in Pubmed: 2200925.
7. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of 
renal function: new insights into old concepts. Clin Chem. 1992; 38(10): 
1933–1953, indexed in Pubmed: 1394976.
8. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction 
and blood-pressure control on the progression of chronic renal disease. 
Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994; 
330(13): 877–884, doi: 10.1056/NEJM199403313301301, indexed in 
Pubmed: 8114857.
9. Sapirstein LA, Vidt DG, Mandel MJ, et al. Volumes of distribution and 
clearances of intravenously injected creatinine in the dog. Am J Physiol. 
1955; 181(2): 330–336, doi: 10.1152/ajplegacy.1955.181.2.330, indexed 
in Pubmed: 14376619.
10. Brien TG, O’Hagan R, Muldowney FP. Chromium -51- EDTA in the determi-
nation of glomerular filtration rate. Acta Radiol Ther Phys Biol. 1969; 8(6): 
523–529, indexed in Pubmed: 4983177.
11. Chantler C, Barratt TM. Estimation of glomerular filtration rate from plasma 
clearance of 51-chromium edetic acid. Arch Dis Child. 1972; 47(254): 
613–617, indexed in Pubmed: 4625784.
12. Sambataro M, Thomaseth K, Pacini G, et al. Plasma clearance rate of 
51Cr-EDTA provides a precise and convenient technique for measurement 
of glomerular filtration rate in diabetic humans. J Am Soc Nephrol. 1996; 
7(1): 118–127, indexed in Pubmed: 8808118.
13. Chantler C, Garnett ES, Parsons V, et al. Glomerular filtration rate measure-
ment in man by the single injection methods using 51Cr-EDTA. Clin Sci. 
1969; 37(1): 169–180, indexed in Pubmed: 4980763.
14. Farmer CD, Tauxe WN, Maher FT, et al. Measurement of renal function with 
radioiodinated diatrizoate and omicron-iodohippurate. Am J Clin Pathol. 
1967; 47(1): 9–16, indexed in Pubmed: 6015988.
15. Russell CD, Bischoff PG, Kontzen FN, et al. Measurement of glomerular 
filtration rate: single injection plasma clearance method without urine collec-
tion. J Nucl Med. 1985; 26(11): 1243–1247, indexed in Pubmed: 3903074.
16. Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 
807 patients with neuroendocrine tumours: the value and limitations of 
clinical factors. Eur J Nucl Med Mol Imaging. 2015; 42(1): 5–19, doi: 
10.1007/s00259-014-2893-5, indexed in Pubmed: 25273832.
17. Sabet A, Ezziddin K, Pape UF, et al. Accurate assessment of long-term 
nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-oc-
treotate. Eur J Nucl Med Mol Imaging. 2013; 41(3): 505–510, doi: 
10.1007/s00259-013-2601-x.
18. Geist BK, Diemling M, Staudenherz A. Glomerular Filtration Rate and Error 
Calculation Based on the Slope-Intercept Method with Chromium-51 Ethylen-
ediaminetetraacetic Acid via a New Clinical Software: GFRcalc. Med Princ Pract. 
2016; 25(4): 368–373, doi: 10.1159/000445028, indexed in Pubmed: 26925969.
19. Brøchner-Mortensen J. Routine methods and their reliability for assessment 
of glomerular filtration rate in adults, with special reference to total [51Cr]
EDTA plasma clearance. Dan Med Bull. 1978; 25(5): 181–202, indexed in 
Pubmed: 100271.
20. Hagstam KE, Nordenfelt I, Svensson L, et al. Comparison of different meth-
ods for determination of glomerular filtration rate in renal disease. Scand 
J Clin Lab Invest. 1974; 34(1): 31–36, doi: 10.3109/00365517409061818, 
indexed in Pubmed: 4213006.
21. Surma MJ. Comparison of accuracy and precision of three methods of GFR 
determination. Eur J Nucl Med Mol Imag. 2009; 36(S2): 438.
22. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring 
body surface area: a height-weight formula validated in infants, children, 
and adults. J Pediatr. 1978; 93(1): 62–66, indexed in Pubmed: 650346.
